Loading quotes...
Forecast
| Buy |
7 |
| Hold |
9 |
| Sell |
1 |
News Go to news feed
Smith & Nephew stock falls to 52-week low of $27.54
Smith & Nephew's stock hit a 52-week low at $27.54 and fell 26.81% over the past year. In the second quarter the company reported revenue of $1.6 billion, missing the $1.64 billion estimate; growth in sports medicine and wound care was offset by weakness in US orthopedics and at SANTYL. Analysts including Morgan Stanley and JPMorgan downgraded the stock and cut price targets, while management's dividend continuity, a 2.15% dividend yield and generous share buybacks were cited as signals of confidence. » More on de.investing.com
Smith & Nephew starts cash tender offer for 2030 notes up to $250 million
Smith & Nephew is offering to repurchase its senior notes (coupon 2.032%) due October 14, 2030, for up to $250 million aggregate principal amount; $900 million of these securities are currently outstanding. A US Treasury (coupon 4.375%, maturing August 31, 2031) plus a fixed spread of 55 basis points serves as the reference; accepted notes will be retired. The aim is debt management and to extend average maturity; the offer is conditional on a planned, simultaneous issuance of new senior notes due 2036 generating sufficient gross proceeds. Consideration per $1,000 will be determined on September 15, 2026; the offer expires on September 15, 2026, and the expected settlement date is September 18, 2026; if oversubscribed, allocations will be made pro rata. » More on de.investing.com
Smith & Nephew share falls to 52-week low at 28.55 USD
Smith & Nephew’s share hit a new 52-week low of 28.55 USD, leaving the stock about 23.9% lower year-to-date. For the second quarter the company reported revenue of 1.6 billion USD, missing the 1.64 billion USD forecast; adjusted revenue rose 1.6%, reported revenue rose 2.8%. Weaknesses in sports medicine and wound care, a softer US orthopedics business and a disappointing performance from SANTYL weighed on the results. Several analysts cut their ratings and price targets, underscoring the cautious outlook and investor pressure. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 2.67B | - |
| Gross profit | 1.9B | - |
| Net profit | 261.65M | - |
| EBITDA | 672.69M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €9.87B |
Number of shares | 837.03M |
52-week high/low | €16.42 - €11.45 |
Dividend yield | 2.49% |
Dividends TTM | €0.33 |
Next dividend | €0.14 |
Beta | 0.54 |
P/E ratio | 19.51 |
PEG ratio | 0.59 |
P/B ratio | 2.42 |
P/S ratio | 1.95 |
Company profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
| Name | SMITH & NEPHEW |
| CEO | Deepak S. Nath |
| Headquarters | Watford,
hr United Kingdom |
| Website | |
| Sector | Health Care |
| Industry | Health Care Technology |
| IPO | 07/01/1988 |
| Employees | 18,362 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | SNNUF |
London Stock Exchange | SN.L |
Frankfurt | NPW1.F |
Düsseldorf | NPW1.DU |
London | SN.L |
SIX | NPW1.SW |
München | NPW1.MU |